SPY328.73+5.23 1.62%
DIA271.70+3.60 1.34%
IXIC10,913.56+241.30 2.26%

Morgan Stanley Maintains Overweight on Ascendis Pharma, Raises Price Target to $179

Morgan Stanley maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $177 to $179.

 · 
Morgan Stanley maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $177 to $179.